Why is United Therapeutics stock surging today?

United Therapeutics stock surged 13.7% in afternoon trading after a federal court in Delaware handed the company a pivotal intellectual property victory over rival Liquidia Corporation. The U.S. District Court for the District of Delaware ruled that Liquidia infringed claims 1 and 14 of United Therapeutics’ U.S. Patent No. 11,826,327, which covers the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD) using inhaled treprostinil — the active ingredient in United Therapeutics’ Tyvaso therapy. Liquidia’s shares were halted and fell sharply on the news, while United Therapeutics shares hit a session high of $556.20 before pulling back slightly.

The ruling carries significant commercial weight because it directly limits Liquidia’s ability to market its competing YUTREPIA inhalation powder in the PH-ILD indication; Liquidia announced plans to revise its drug label to remove that indication while also pursuing an appeal. The court victory arrives at a strategically important moment for United Therapeutics, which is also completing a $477.6 million accelerated share repurchase with Citibank — the final tranche of a $2 billion buyback authorization — that has been steadily reducing its share count. Additionally, the FDA’s acceptance of the company’s supplemental NDA for nebulized Tyvaso in idiopathic pulmonary fibrosis, with a review decision expected in late April 2027, adds a meaningful pipeline catalyst to the story.

On the macro front, broader U.S. equity markets were modestly positive today, with the Nasdaq gaining 0.8% and the S&P 500 adding 0.3%, supported by softer-than-expected PCE inflation data that eased concerns about further Federal Reserve rate hikes. The Pharmaceuticals & Medical Research sector, however, was slightly negative on the session, underscoring how dramatically United Therapeutics outperformed its peer group. Analyst sentiment had been mixed heading into today, with a recent Goldman Sachs Sell initiation at a $321 target contrasting with a broader analyst consensus "Moderate Buy" rating and an average price target of $621.

The combination of a clear-cut legal win that fortifies the Tyvaso franchise, an ongoing share buyback reducing float, and a constructive pipeline regulatory calendar converged today to produce one of the stock’s strongest single-session moves in recent memory, pushing shares well above their 52-week low of $409.07 and back toward the upper half of their annual trading range.